GSK (NYSE:GSK) Shares Gap Up - Should You Buy?

Key Points

• GSK shares jumped from a $48.13 close to a $50.29 open, last trading at $49.73. The move followed encouraging pipeline news, particularly positive Phase III data for Ris-Riz in relapsed small-cell lung cancer, which reduced the risk of death by 54%.
• GSK also plans to expand its U.S. submission for Jideytro after positive results, potentially broadening the drug’s use and commercial opportunity. The company views these developments as evidence of pipeline momentum and support for future growth.
• Despite stronger-than-expected quarterly earnings and a dividend increase to $0.4515 per share, analyst sentiment remains cautious: GSK has a consensus “Hold” rating and a $53 price target, with coverage including underweight, neutral and hold recommendations.

GSK PLC Sponsored ADR (NYSE:GSK - Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $48.13, but opened at $50.29. GSK shares last traded at $49.73, with a volume of 744,536 shares trading hands.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK reported positive Phase III overall-survival data for its Ris‑Rez program in relapsed small-cell lung cancer in China. The treatment reportedly reduced the risk of death by 54% and met the trial’s primary endpoint, potentially supporting future regulatory filings and adding a meaningful oncology growth opportunity. GSK PLC Announces Positive Phase III Overall Survival Data
• Positive Sentiment: Additional coverage highlighted a 94% response rate and a successful late-stage trial for GSK’s potential small-cell lung cancer drug, reinforcing expectations that the program could become an important pipeline asset. GSK Reports 94% Response Rate for Lung Cancer Drug Trial
• Positive Sentiment: GSK plans to expand its U.S. submission for Jideytro following positive results, while separate reports cited efficacy when the drug was used in earlier-line treatment. A broader label or earlier use could increase the medicine’s commercial potential if regulators accept the data. GSK Plans Expanded US Submission for Jideytro
• Positive Sentiment: GSK characterized the Ris‑Rez and Jideytro updates as evidence of pipeline momentum, which may help offset investor concerns about long-term pharmaceutical growth and patent exposure. GSK Highlights Pipeline Momentum
• Neutral Sentiment: GSK also discussed using health data from the Greater Bay Area to improve healthcare policy. The initiative may support research and regional relationships but is unlikely to materially affect near-term earnings. Greater Bay Area Healthcare Policy Data

Wall Street Analyst Weigh In

Several analysts have commented on the company. Weiss Ratings downgraded GSK from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Wednesday, July 29th. Morgan Stanley reissued an "underweight" rating on shares of GSK in a research note on Tuesday, August 25th. Citigroup began coverage on shares of GSK in a research report on Friday, July 24th. They set a "neutral" rating on the stock. Wall Street Zen downgraded GSK from a "buy" rating to a "hold" rating in a research note on Saturday, August 1st. Finally, HSBC reissued a "hold" rating on shares of GSK in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, GSK currently has a consensus rating of "Hold" and a consensus price target of $53.00.

GSK Price Performance

The stock has a market cap of $100.80 billion, a price-to-earnings ratio of 15.59, a price-to-earnings-growth ratio of 2.02 and a beta of 0.35. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. The business's fifty day simple moving average is $51.29 and its 200 day simple moving average is $52.75.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.02 billion. During the same quarter in the previous year, the firm earned $0.47 earnings per share. The business's revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Research analysts predict that GSK PLC Sponsored ADR will post 4.81 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Shareholders of record on Friday, August 14th will be given a dividend of $0.4515 per share. This represents a $1.81 dividend on an annualized basis and a yield of 3.6%. The ex-dividend date is Friday, August 14th. This is a boost from GSK's previous quarterly dividend of $0.44. GSK's dividend payout ratio is 55.63%.

Institutional Investors Weigh In On GSK

A number of hedge funds and other institutional investors have recently made changes to their positions in GSK. IHT Wealth Management LLC grew its holdings in GSK by 1.3% during the 4th quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company's stock worth $736,000 after acquiring an additional 188 shares in the last quarter. Bogart Wealth LLC raised its holdings in shares of GSK by 15.3% in the 1st quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company's stock valued at $83,000 after purchasing an additional 200 shares in the last quarter. Natural Investments LLC raised its holdings in shares of GSK by 2.8% in the 2nd quarter. Natural Investments LLC now owns 7,726 shares of the pharmaceutical company's stock valued at $405,000 after purchasing an additional 211 shares in the last quarter. HF Advisory Group LLC lifted its position in shares of GSK by 3.5% in the 2nd quarter. HF Advisory Group LLC now owns 7,578 shares of the pharmaceutical company's stock worth $397,000 after purchasing an additional 259 shares during the period. Finally, NBT Bank N A NY lifted its position in shares of GSK by 1.9% in the 1st quarter. NBT Bank N A NY now owns 16,568 shares of the pharmaceutical company's stock worth $914,000 after purchasing an additional 315 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

About GSK

GSK plc is a global biopharmaceutical company headquartered in Brentford, England. The company researches, develops and manufactures medicines and vaccines for the prevention and treatment of disease, serving patients and healthcare providers in markets around the world.

GSK focuses on specialty medicines and vaccines in areas including infectious diseases, HIV, respiratory disease, immunology and oncology. Its products include prescription medicines, long-acting treatments and vaccines designed to protect against diseases such as shingles, meningitis, influenza and respiratory syncytial virus (RSV).

The company was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.